Skip to main content
OpenTrials
Completed

NCT Number: NCT00202553

S90652 in Paediatric Hypertension

The aim of the study is to assess the acceptability, safety and pharmacokinetics and effects on blood pressure of a paediatric formulation of perindopril given in hypertensive children

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Hôpital Necker Enfants Malades

Paris, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hypertensive children

Exclusion criteria

  • Renal failure
  • Unstable renal function
  • Hyperkaliemia

Treatment and study plan

perindopril

Drug

Primary outcomes

  1. Safety assessed from the patient's (parents) complaints and the clinical follow-up

Secondary outcomes

  1. Acceptability, efficacy, pharmacokinetics

Sponsors and collaborators

Lead sponsor

Institut de Recherches Internationales Servier

Other

Registry information

Official study title

Acceptability, Safety, Pharmacokinetics and Effects on Blood Pressure of a Daily Dose of 0.025 to 0.135 Milligram Per Kilogram of S90652, a Paediatric Formulation of Perindopril, in 2-16 Years Old Hypertensive Children - 3 Month Study

Important dates

Study start
2003
Study completion
2006
First posted
Sep 20, 2005
Registry last updated
Apr 11, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.